Gilde Healthcare
Gilde Healthcare Acquires Majority Stake in Danish Drug Development Consultancy KLIFO to Support International Growth Ambitions
Gilde Healthcare Acquires Majority Stake in Danish Drug Development Consultancy KLIFO to Support International Growth Ambitions
Northern European integrated drug development consultancy aims to further expand service offering and geographical footprint
UTRECHT, the Netherlands and COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE) Gilde Healthcare, a specialized healthcare investor, and KLIFO A/S, a leading Northern European drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance their drug development projects, today announce that Gilde Healthcare’s Private Equity fund has acquired a majority stake in KLIFO. Gilde Healthcare aims to support KLIFO’s growth in the dynamically developing pharma outsourcing sector.
Northern European integrated drug development consultancy aims to further expand service offering and geographical footprintUTRECHT, the Netherlands and COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE)
কোভিড-১৯: গ্লোবের টিকা কতদূর? bdnews24.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bdnews24.com Daily Mail and Mail on Sunday newspapers.
Quartesian Surpasses 250 Studies Employing Medrio s EDC Platform
News provided by
Share this article
Share this article
PRINCETON, N.J., May 4, 2021 /PRNewswire/ Quartesian, a multinational Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, announced today that they have deployed Medrio s cloud-based EDC platform for 265 clinical studies world-wide.
Quartesian s partnership with Medrio began in 2009 and they were an early participant in the Medrio Partner Program providing expanded services to better support mutual sponsor and CRO customers. Quartesian has contributed to both product development and marketing during this long relationship as part of Medrio s Customer Advisory Board. Quartesian and Medrio understand the value of data-driven trials. Surpassing 250 studies together means that the data speaks for itself, said Nicole Latimer, CEO of Medrio. Quartesian continues to disrupt the clinical data services industry by unl
Updated May 04, 2021 · 08:18 pm A model of the Bharat Biotech’s indigenous vaccine, Covaxin.
The intellectual property rights for the use of Bharat Biotech’s indigenous vaccine, Covaxin, was shared between the drug manufacturer and the Indian Council of Medical Research, with both entities gaining the royalty payments, reported
The Hindu.
“The Public-Private Partnership was executed under a formal Memorandum of Understanding (MoU) between the ICMR and the BBIL [Bharat Biotech International Limited] which includes a royalty clause for the ICMR on net sales and other clauses like prioritisation of in-country supplies,” ICMR Director-General Balram Bhargava told
The Hindu in an email conversation.